A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. Kim RD, Kovari BP, Martinez M, Xie H, et al. Eur J Cancer 2022;169:93-102.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kim RD, Kovari BP, Martinez M, Xie H, et al. A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. Eur J Cancer 2022;169:93-102.
PMID: 35526308